High-Dosed Intravenous Iron Replacement Therapy Does Not Hinder Drug-Induced Amelioration of Disease Activity in IBD Patients with Iron Deficiency Anemia
January 2018
in “
Journal of Crohn s and Colitis
”
TLDR High-dose intravenous iron therapy doesn't interfere with treatment improvements in IBD patients with iron deficiency anemia.
This study assessed the impact of high-dosed intravenous ferric carboxymaltose (FCM) on inflammatory activity in 224 IBD patients with iron deficiency anaemia across 101 centers in Germany. Over approximately 12 weeks, patients received a mean total FCM dose of 1139 mg. The study found that high-dosed FCM did not hinder drug-induced improvement of disease activity. Significant reductions in CRP levels indicated decreased inflammation, and improvements were observed in clinical disease indices (CDAI/CAI) and symptoms such as fatigue and hair loss. The therapy was effective regardless of baseline hemoglobin levels, and patients showed increased hemoglobin, serum ferritin, and transferrin saturation, with reduced CRP levels and symptoms.